Trial Profile

Phase I/IIa, Non-Randomised, Open-Label Dose Escalation and Expansion Trial With Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Metastatic or Unresectable, Locally Advanced Malignant Solid Tumors

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 08 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Isunakinra (Primary)
Indications Anal cancer; Appendiceal cancer; Cholangiocarcinoma; Colorectal cancer; Pancreatic cancer; Prostate cancer; Solid tumours; Triple negative breast cancer
Focus Adverse reactions
Sponsors Buzzard Pharmaceuticals

06 Aug 2024 Status changed from recruiting to completed.
06 Jun 2023 Results (n=15), presented at the 59th Annual Meeting of the American Society of Clinical Oncology
20 Feb 2023 Planned End Date changed from 15 Jul 2023 to 15 Dec 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com